Dilon Devices to Present at the 2018 Canaccord Genuity Medical Technologies and Diagnostics Forum

By Nov 15, 2018 November 19th, 2018 News

(November 15, 2018 – Atlanta, GA and New York) Lori Chmura, CEO of Dilon Devices, maker of the successful MarginProbe device is scheduled to present at the Canaccord Genuity Medical Technologies and Diagnostics Forum on Thursday, November 15th at 2:30 p.m. EST at the Westin Grand Central in New York, NY.

The presentation will be available as a webcast at dunemedical.com/investors.

Dilon Devices is a commercial-stage company revolutionizing tissue characterization technology in breast cancer surgery, diagnosis and targeted treatment with its proprietary Radio-Frequency Spectroscopy Technology (RFST). Dune’s first commercial product, MarginProbe®, in routine commercial use in 70 hospitals and in over 16,000 surgeries in the US and Israel, has been proven to identify positive margins during breast conservation surgery, enabling surgeons to immediately remove additional microscopic residual cancer, thereby reducing the need for repeat surgeries. The second generation of the RFST, in development, serves as a platform to enhance diagnostic accuracy by providing pathologists with tissue characterization data alongside biopsy samples to increase interpretation accuracy and eliminate unnecessary procedures and costs.

Dune is entering a phase of commercial growth and expansion of its RFST platform to establish RFST data as a unique tissue biomarker that provides information complementary to molecular (e.g., genomic) biomarkers for optimal personalized treatment selection and adoption of new therapies. This Smart Biopsy Device incorporates its proprietary RF spectroscopy to enable the radiologist to receive real-time data from the tip of the needle. The project is fully funded by the extremely competitive European Union Horizon 2020 grant awarded to Dune in 2016. 

About Dilon Devices
“Imagine not having to wonder, did we get it all?”
At Dilon Devices, we believe in reducing the anxiety that waiting for pathology results places on a patient and their families. Our solutions, which are developed on a first-of-its-kind RF Spectroscopy platform, can differentiate cancerous from healthy tissue based on electromagnetic properties, making it possible for patients and physicians to answer the question, “did we get it all?” For more info: dunemedical.com

Jean-Luc Vanhulst
Write2Market for Dilon Devices
+1 (347 )- 453 7686